A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 17, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions

Renal Cell CarcinomaFirst-line TreatmentNon Clear Cell Renal Cell CarcinomaSarcomatoid Renal Cell Carcinoma

Interventions

DRUG

AK104

Anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)

DRUG

Axitinib

An oral, small molecule, TKI selective for VEGFRs; 5mg bid orally

Trial Locations (1)

RECRUITING

West China Hospital, Chengdu

All Listed Sponsors

lead

Hao Zeng

OTHER